Status:
TERMINATED
Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
Lead Sponsor:
Pfizer
Conditions:
Pulmonary Arterial Hypertension
Pulmonary Hypertension
Eligibility:
All Genders
16-80 years
Phase:
PHASE3
Brief Summary
This protocol is for subjects with pulmonary arterial hypertension and is the first of 3 studies forming the Sitaxsentan efficacy and safety trial with Randomized Prospective Assessment of Adding Sild...
Eligibility Criteria
Inclusion
- Current diagnosis of symptomatic pulmonary arterial hypertension (PAH) classified by one of the following: idiopathic arterial hypertension (IPAH), primary pulmonary hypertension (PPH), familial pulmonary arterial hypertension (FPAH) or pulmonary arterial hypertension (PAH) associated with connective tissue diseases. Has WHO functional class III symptoms.
Exclusion
- Previous exposure to an endothelin receptor antagonist (ETRA) such as sitaxsentan, bosentan or ambrisentan.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
183 Patients enrolled
Trial Details
Trial ID
NCT00795639
Start Date
December 1 2008
End Date
March 1 2011
Last Update
March 24 2015
Active Locations (85)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Fountain Valley, California, United States, 92708
2
Pfizer Investigational Site
Mather, California, United States, 95655
3
Pfizer Investigational Site
Sacramento, California, United States, 95817
4
Pfizer Investigational Site
Englewood, Colorado, United States, 80113